Literature DB >> 1503454

A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone.

A M Figueiredo1, J D Connor, A Severin, M V Vaz Pato, A Tomasz.   

Abstract

A beta-lactam-resistant serotype 23F Streptococcus pneumoniae clinical isolate from the cerebrospinal fluid of a pediatric patient from California is unusual in that the MICs of cefotaxime and ceftriaxone (2.5 micrograms/ml each) are higher than that of benzylpenicillin (0.3 micrograms/ml); the isolate also has patterns of penicillin-binding proteins and of cell wall peptides which are atypical compared with those of previously examined penicillin-resistant pneumococci.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1503454      PMCID： PMC189481          DOI： 10.1128/AAC.36.4.886

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci.

Authors:  P F Viladrich; F Gudiol; J Liñares; G Rufi; J Ariza; R Pallares
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

2.  Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics.

Authors:  J S Bradley; J D Connor
Journal:  Pediatr Infect Dis J       Date:  1991-11       Impact factor: 2.129

3.  Penicillin-binding protein families: evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci.

Authors:  D Jabes; S Nachman; A Tomasz
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

4.  Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986.

Authors:  K P Klugman; H J Koornhof
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

5.  Antimicrobial susceptibility testing of pneumococci. 2. Determination of optimal disc diffusion test for detection of penicillin G resistance.

Authors:  M R Jacobs; M N Gaspar; R M Robins-Browne; H J Koornhof
Journal:  J Antimicrob Chemother       Date:  1980-01       Impact factor: 5.790

6.  Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin.

Authors:  J I Ward; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

7.  Penicillin resistance and defective lysis in clinical isolates of pneumococci: evidence for two kinds of antibiotic pressure operating in the clinical environment.

Authors:  P Moreillon; A Tomasz
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

8.  A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillin-resistant pneumococci.

Authors:  J Garcia-Bustos; A Tomasz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205
  8 in total
  26 in total

1.  Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.

Authors:  J Gerber; A Smirnov; A Wellmer; J Ragheb; J Prange; E Schütz; K Wettich; S Kalich; R Nau
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates.

Authors:  Y Asahi; Y Takeuchi; K Ubukata
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Activity of vancomycin, teicoplanin and cephalosporins against penicillin-susceptible and penicillin-intermediate Streptococcus pneumoniae.

Authors:  V G Loo; J Lavallée; D McAlear; H G Robson
Journal:  Can J Infect Dis       Date:  1995-03

4.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

5.  Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Description of two new isolates of Streptococcus pneumoniae in spain that are highly resistant to cefotaxime.

Authors:  J Ruiz; M Sempere; E Simarro; A Fenoll
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

7.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

8.  Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

Authors:  B Barry; M Muffat-Joly; J Bauchet; F Faurisson; P Gehanno; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

9.  In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae.

Authors:  P Chavanet; N Peyrard; A Pechinot; M Buisson; M Duong; C Neuwirth; A Kazmierczak; H Portier
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

10.  Moxifloxacin in the therapy of experimental pneumococcal meningitis.

Authors:  H Schmidt; A Dalhoff; K Stuertz; F Trostdorf; V Chen; O Schneider; C Kohlsdorfer; W Brück; R Nau
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.